As yet, there exists no consensus as to whether proactive or reactive monitoring is the most appropriate approach in patients with inflammatory bowel disease (IBD) who receive infliximab therapy.
In therapeutic drug monitoring (TDM), measurements of trough levels can be used to guide adjustments of treatment intensity as a way to minimize the risk of treatment failure. In some cases, patients are monitored proactively; in other cases, patients are monitored reactively, or only when they report signs or symptoms that may point to a loss of response to a drug. As yet, there exists no consensus as to whether proactive or reactive TDM is the most appropriate approach in patients with inflammatory bowel disease (IBD) who receive infliximab therapy.
Some research has pointed to the superiority of proactive TDM; one recent study from Portugal in 205 patients with IBD, 56 of whom received proactive monitoring, showed that those who were proactively monitored received more treatment escalation, needed fewer surgeries, and had higher rates of mucosal healing than their counterparts who received reactive monitoring.1
However, in somewhat contrasting findings, researchers from Spain reported in a new study that in the first year of treatment with biosimilar infliximab CT-P13 (Inflectra, Remsima), patients with IBD did not have improved response or remission rates with the use of proactive monitoring versus reactive monitoring.2
In the study, 77 patients with IBD, 23 of whom had ulcerative colitis and 54 of whom had Crohn disease, received either proactive monitoring (n = 41) or reactive monitoring (n = 36). All of these patients were starting treatment with CT-P13.
The proactive monitoring group had levels of infliximab and antidrug antibodies measured at week 14, and those patients whose drug levels were too low received intensification, regardless of their clinical response to infliximab.
At week 14, 58.5% of the proactive monitoring group and 63.9% of the reactive monitoring group had achieved clinical remission. In the 2 groups respectively, 80.5% and 80.6%, respectively, had at least a partial response. At week 54, 61.0% of the proactive monitoring group and 77.8% of the reactively monitoring group were in clinical remission, and 73.2% and 80.6%, respectively, had at least a partial response.
Of the 13 patients in the proactive group who had their treatment intensified, there were no significant differences observed versus the reactive monitoring group in terms of secondary loss of response to infliximab.
According to the authors, proactive management does not improve response or remission rates for patients receiving CT-P13 in the first year versus reactive monitoring, and treatment intensification does not appear to prevent secondary loss of response in the first year of therapy.
References
1. Fernandes SR, Bernardo S, Simões C, et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease [published online June 27, 2019]. Inflamm Bowel Dis. doi: 10.1093/ibd/izz131.
2. González AE, Segura PS, Lara DO, et al. Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease [published online November 27, 2019]. Med Clin (Barc). doi: 10.1016/j.medcli.2019.07.025.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.